Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes: A workshop report with focus on novel entities and a literature review including paediatric cases
暂无分享,去创建一个
M. Rozman | L. Saft | S. Lazzi | U. Gianelli | H. Kvasnicka | L. Boudová
[1] A. Isaza,et al. Myeloid/lymphoid neoplasm with eosinophilia and BCR/FGFR1 rearrangement with transformation to cortical T-lymphoblastic lymphoma and erythroid precursors: a case report , 2023, Journal of Medical Case Reports.
[2] B. Pitel,et al. A TRIP11: FLT3 gene fusion in a patient with myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions: a case report and review of the literature. , 2023, Cold Spring Harbor molecular case studies.
[3] A. Yoshimi,et al. Rare and potentially fatal - Cytogenetically cryptic TNIP1::PDGFRB and PCM1::FGFR1 fusion leading to myeloid/lymphoid neoplasms with eosinophilia in children. , 2023, Cancer genetics.
[4] D. Arber,et al. Updates on eosinophilic disorders , 2022, Virchows Archiv.
[5] M. Loh,et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. , 2022, Blood.
[6] Y. Natkunam,et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms , 2022, Leukemia.
[7] M. Robin,et al. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT , 2022, Bone Marrow Transplantation.
[8] Weiling Li,et al. Identification of a novel HOOK3-FGFR1 fusion gene involved in activation of the NF-kappaB pathway , 2021, Cancer cell international.
[9] J. Gotlib,et al. World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management , 2022 .
[10] R. Ketterling,et al. A rare case of atypical chronic myeloid leukemia associated with t(8;22)(p11.2;q11.2)/ BCR-FGFR1 rearrangement: A case report and literature review. , 2021, Cancer genetics.
[11] K. Roskin,et al. Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance. , 2021, Blood advances.
[12] A. Bagg,et al. Myeloid/lymphoid neoplasms with FLT3 rearrangement , 2021, Modern Pathology.
[13] N. Shukla,et al. ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML. , 2021, Blood advances.
[14] Wenyu Yang,et al. Myeloid neoplasm with eosinophilia and rearrangement of platelet-derived growth factor receptor beta gene in children: Two case reports , 2021, World journal of clinical cases.
[15] L. Rimsza,et al. Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2. , 2020, American Journal of Clinical Pathology.
[16] D. Arber,et al. Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement. , 2020, Blood advances.
[17] L. Medeiros,et al. Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement. , 2020, Leukemia research.
[18] Lindsay A. M. Rein,et al. Transformation to erythroblastic sarcoma from myeloid neoplasm with PCM1-JAK2. , 2020, Blood.
[19] L. Osnes,et al. Partial Response to Sorafenib in a Child With a Myeloid/Lymphoid Neoplasm, Eosinophilia, and a ZMYM2-FLT3 Fusion. , 2020, Journal of pediatric hematology/oncology.
[20] B. Pitel,et al. Integrated genomic analysis using chromosomal microarray, fluorescence in situ hybridization and mate pair analyses: Characterization of a cryptic t(9;22)(p24.1;q11.2)/BCR-JAK2 in myeloid/lymphoid neoplasm with eosinophilia. , 2020, Cancer genetics.
[21] P. D. Dal Cin,et al. Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia. , 2020, Blood advances.
[22] M. Arcila,et al. Myeloid/lymphoid neoplasms with eosinophilia/basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition , 2020, Haematologica.
[23] T. Haferlach,et al. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1‐JAK2, BCR‐JAK2 and ETV6‐ABL1 fusion genes , 2020, American journal of hematology.
[24] P. Szankasi,et al. Chronic myelomonocytic leukemia with ETV6-ABL1 rearrangement and SMC1A mutation. , 2019, Cancer genetics.
[25] A. K. Chao,et al. Fusion driven JMML: a novel CCDC88C–FLT3 fusion responsive to sorafenib identified by RNA sequencing , 2019, Leukemia.
[26] S. Lorenz,et al. Novel GTF2I–PDGFRB and IKZF1–TYW1 fusions in pediatric leukemia with normal karyotype , 2019, Experimental Hematology & Oncology.
[27] L. Medeiros,et al. Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors. , 2018, Cancer genetics.
[28] A. Bagg,et al. Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study , 2018, Modern Pathology.
[29] A. Takaori-Kondo,et al. Allogeneic hematopoietic stem cell transplantation for 8p11 myeloproliferative syndrome with BCR-FGFR1 gene rearrangement: a case report and literature review , 2018, Bone Marrow Transplantation.
[30] V. Najfeld,et al. Myeloid/lymphoid neoplasms with FGFR1 rearrangement , 2018, Leukemia & lymphoma.
[31] T. Haferlach,et al. Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2 , 2018, Haematologica.
[32] K. Roskin,et al. A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia. , 2017, Cancer genetics.
[33] W. Tapper,et al. Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia , 2017, Leukemia.
[34] L. Medeiros,et al. Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase. , 2017, Human pathology.
[35] V. Miller,et al. Novel PDGFRB fusions in childhood B- and T-acute lymphoblastic leukemia , 2017, Leukemia.
[36] A. Reiter,et al. Myeloid neoplasms with eosinophilia. , 2017, Blood.
[37] D. D. Giacomo,et al. The importance of cytogenetic and molecular analyses in eosinophilia-associated myeloproliferative neoplasms: an unusual case with normal karyotype and TNIP1- PDGFRB rearrangement and overview of PDGFRB partner genes , 2017, Leukemia & lymphoma.
[38] B. Petit,et al. A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3? , 2016, Leukemia.
[39] C. Harrison,et al. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. , 2016, Blood.
[40] V. Saha,et al. Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6–LYN gene fusion , 2016, Blood Cancer Journal.
[41] M. Loh,et al. Characterization of leukemias with ETV6-ABL1 fusion , 2015, Haematologica.
[42] P. Koduru,et al. Myeloid and lymphoid neoplasm with abnormalities of FGFR1 presenting with trilineage blasts and RUNX1 rearrangement: a case report and review of literature. , 2015, American journal of clinical pathology.
[43] W. Tapper,et al. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes , 2015, Annals of Hematology.
[44] Heather L. Mulder,et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. , 2014, The New England journal of medicine.
[45] B. Bain,et al. Should myeloid and lymphoid neoplasms with PCM1‐JAK2 and other rearrangements of JAK2 be recognized as specific entities? , 2014, British journal of haematology.
[46] H. Matsuoka,et al. Extramedullary T-lymphoid blast crisis of an ETV6/ABL1-positive myeloproliferative neoplasm with t(9;12)(q34;p13) and t(7;14)(p13;q11.2) , 2014, Annals of Hematology.
[47] Teruhiko Yoshida,et al. ATF7IP as a novel PDGFRB fusion partner in acute lymphoblastic leukaemia in children , 2014, British journal of haematology.
[48] H. Ohno,et al. inv(2)(p23q13)/RAN-binding protein 2 (RANBP2)–ALK fusion gene in myeloid leukemia that developed in an elderly woman , 2014, International Journal of Hematology.
[49] E. Nacheva,et al. Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review , 2013, Molecular Cytogenetics.
[50] M. Cazzola,et al. Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] A. Anguiano,et al. B-Lymphoblastic Leukemia/Lymphoma Associated with t(8;13)(p11;q12)/ZMYM2 (ZNF198)-FGFR1: Rare Case and Review of the Literature , 2013, Acta Haematologica.
[52] M. Salama,et al. Congenital and Childhood myeloproliferative disorders with eosinophilia responsive to imatinib , 2012, Pediatric blood & cancer.
[53] C. Deswarte,et al. RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation , 2012, Leukemia.
[54] G. Webersinke,et al. Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia , 2011, Diagnostic pathology.
[55] W. Tse,et al. Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3‐PDGFRB Fusion , 2011, Pediatric blood & cancer.
[56] P. Koduru,et al. Novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2) in B-acute lymphoblastic leukemia. , 2010, Leukemia research.
[57] Y. Zhai,et al. Biphenotypic hematologic malignancy: a case report of the 8p11 myeloproliferative syndrome in a child. , 2010, Journal of pediatric hematology/oncology.
[58] L. Medeiros,et al. 8p11 myeloproliferative syndrome: a review. , 2010, Human pathology.
[59] A. Tefferi,et al. Chromosome 8p11.2 translocations: Prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution , 2010, American journal of hematology.
[60] R. Naeem,et al. Molecular monitoring of 8p11 myeloproliferative syndrome in an infant. , 2009, Journal of pediatric hematology/oncology.
[61] J. Aster,et al. Novel SSBP2‐JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre‐B acute lymphocytic leukemia , 2008, Genes, chromosomes & cancer.
[62] B. Bain,et al. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. , 2007, Immunology and allergy clinics of North America.
[63] A. Reiter,et al. Two novel imatinib‐responsive PDGFRA fusion genes in chronic eosinophilic leukaemia , 2007, British journal of haematology.
[64] S. Cheng,et al. Clonal evolution of 8p11 stem cell syndrome in a 14-year-old Chinese boy: a review of literature of t(8;13) associated myeloproliferative diseases. , 2007, Leukemia research.
[65] T. Haferlach,et al. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2‐PDGFRA fusion gene , 2006, Genes, chromosomes & cancer.
[66] F. Grand,et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia , 2006, Leukemia.
[67] H. F. Barker,et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. , 2005, Cancer research.
[68] Ricardo C T Aguiar,et al. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. , 2003, Blood.
[69] F. Salvatore,et al. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations , 2002, Oncogene.
[70] A. Reiter,et al. The 8p11 Myeloproliferative Syndrome: A Distinct Clinical Entity Caused by Constitutive Activation of FGFR1 , 2002, Acta Haematologica.
[71] P. Marynen,et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. , 1997, Blood.
[72] C. E. van der Schoot,et al. A young child with acquired t(8;9)(p11;q34): additional proof that 8p11 is involved in mixed myeloid/T lymphoid malignancies. , 1996, Leukemia.
[73] A. Matsuzaki,et al. Chronic myelomonocytic leukaemia with t(8;9)(p11;q34) in childhood: an example of the 8p11 myeloproliferative disorder? , 1996, British journal of haematology.
[74] R. Aguiar,et al. A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review. , 1995, Leukemia.
[75] A. Keating,et al. Neutrophilic myelofibrosis presenting as philadelphia chromosome negative BCR non‐rearranged chronic myeloid leukemia , 1990, American journal of hematology.
[76] S. Lawler,et al. A myeloproliferative disease in two infants associated with eosinophilia and chromosome t(1;5) translocation , 1987, British journal of haematology.
[77] A. Iwama,et al. Identification of a novel TEL–Lyn fusion gene in primary myelofibrosis , 2010, Leukemia.